Gilead Sciences, Inc. and Phenex Pharmaceuticals AG, announced the establishment of a contract in which Gilead is set to acquire the Farnesoid X Receptor (FXR) program of Phenex for the application of small molecule FXR agonists to treat liver ... Read more